Sarcomas – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Sarcomas - Pipeline Review, H1 2012', provides an overview of the Sarcomas therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. 'Sarcomas - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sarcomas.
- A review of the Sarcomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sarcomas pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sarcomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sarcomas pipeline depth and focus of Sarcomas therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Sarcomas Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Sarcomas 13
Sarcomas Therapeutics under Development by Companies 15
Sarcomas Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Pre-Clinical Stage Products 30
Comparative Analysis 30
Sarcomas Therapeutics – Products under Development by Companies 31
Sarcomas Therapeutics – Products under Investigation by Universities/Institutes 34
Companies Involved in Sarcomas Therapeutics Development 53
Bristol-Myers Squibb Company 53
Genzyme Corporation 54
F. Hoffmann-La Roche Ltd. 55
Amgen Inc. 56
Sanofi-Aventis 57
Eli Lilly and Company 58
GlaxoSmithKline plc 59
Merck & Co., Inc. 60
Infinity Pharmaceuticals, Inc. 61
ZIOPHARM Oncology, Inc. 62
Novartis AG 63
ImClone Systems Incorporated 64
Auxilium Pharmaceuticals, Inc. 65
Eisai Co., Ltd. 66
Menarini Group 67
Alchemia Limited 68
Celldex Therapeutics, Inc. 69
AIDA Pharmaceuticals, Inc. 70
Cleveland BioLabs, Inc. 71
Oncolytics Biotech Inc. 72
ARQULE, INC 73
TopoTarget A/S 74
CytRx Corporation 75
Pharmacyclics, Inc. 76
Threshold Pharmaceuticals, Inc. 77
PCI Biotech AS 78
MabVax Therapeutics, Inc. 79
Nanobiotix 80
Morphotek, Inc. 81
Vaccinex, Inc. 82
S*BIO Pte Ltd 83
Neotropix, Inc. 84
Jennerex Biotherapeutics, Inc. 85
Axelar AB 86
MolMed S.p.A. 87
BiPar Sciences, Inc. 88
PharmaMar, S.A. 89
AVEO Pharmaceuticals, Inc. 90
Polaris Group 91
Epeius Biotechnologies Corporation 92
Sarcomas – Therapeutics Assessment 93
Assessment by Monotherapy Products 93
Assessment by Combination Products 94
Assessment by Route of Administration 95
Assessment by Molecule Type 98
Drug Profiles 101
Halaven - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Ombrabulin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Ridaforolimus - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Trabectedin - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Rexin-G - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Taxol - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Sodium Thiosulfate - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Ombrabulin + Cisplatin - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Ifosfamide + Paclitaxel - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
TH-302 + Doxorubicin - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Zymafos + Doxorubicin - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine - Drug Profile 118
Product Description 118
Mechanism of Action 119
R&D Progress 120
Pazopanib - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Filgrastim + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Vincristine sulfate + Radiation therapy - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Ifosfamide + Doxorubicin Hydrochloride + Radiation Therapy - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
rhTPO - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Doxil - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Glivec - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Glivec - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Trofosfamide + Idarubicin + Etoposide - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Gemcitabine + Docetaxel - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Doxorubicin + Ifosfamide - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Topotecan + Carboplatin - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Doxorubicin + Cyclophosphamide + Carboplatin - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Votrient - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Yondelis - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
bevacizumab + filgrastim + pegfilgrastim + docetaxel + gemcitabine hydrochloride - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 143
Dactinomycin + Carboplatin + Cyclophosphamide + Epirubicin + Etoposide + Ifosfamide + Vincristine - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 146
Dactinomycin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Mesna + Vincristine Sulfate - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 149
Filgrastim + Pegfilgrastim + Cyclophosphamide + Dexrazoxane Hydrochloride + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Vincristine Sulfate - Drug Profile 150
Product Description 150
Mechanism of Action 151
R&D Progress 152
Doxorubicin Hydrochloride + Ifosfamide - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Trabectedin - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
Adriamycin + Vindesine - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
Adriamycin + Radiation Therapy - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation Therapy - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation therapy - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
Filgrastim + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation therapy - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
Etoposide + Ifosfamide + Adriamycin + Regional Hyperthermia + Radiotherapy - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 166
Etoposide + Ifosfamide + Adriamycin + Radiotherapy - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
Vincristine + Dactinomycin + Cyclophosphamide + Radiation therapy - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
Sarcomas Therapeutics – Drug Profile Updates 170
Sarcomas Therapeutics – Discontinued Products 178
Sarcomas Therapeutics - Dormant Products 180
Sarcomas – Product Development Milestones 191
Featured News & Press Releases 191
Dec 22, 2011: CytRx Initiates International Phase IIb Clinical Trial With INNO-206 In Advanced Soft Tissue Sarcoma 191
Dec 14, 2011: GlaxoSmithKline Files NDA For Tumor Drug In Japan 192
Dec 07, 2011: ZIOPHARM Receives European Patent Allowance For Palifosfamide 192
Dec 02, 2011: Moffitt Cancer Center Researchers Find MK1775 Active Against Sarcomas 192
Oct 31, 2011: CytRx Announces Favorable Initial Results From Ongoing Phase Ib/II Clinical Trial In Patients With Soft Tissue Sarcomas 193
Oct 28, 2011: Threshold Pharmaceuticals Reports Further Promising Data With TH-302 In Soft Tissue Sarcoma 194
Oct 28, 2011: ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data With Oral And IV Palifosfamide At 2011 CTOS/MSTS Meeting 195
Oct 05, 2011: Merck And ARIAD Announce FDA Acceptance Of New Drug Application Filing For Ridaforolimus 196
Sep 30, 2011: Threshold Initiates Phase III TH-302 Combination Trial In Advanced Soft Tissue Sarcoma 196
Sep 26, 2011: Axelar Reports Good Safety Profile Of AXL1717 In Phase I/II In Cancer Patients 197
Appendix 199
Methodology 199
Coverage 199
Secondary Research 199
Primary Research 199
Expert Panel Validation 200
Contact Us 200
Disclaimer 200
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Sarcomas, H1 2012 13
Products under Development for Sarcomas – Comparative Analysis, H1 2012 14
Number of Products under Development by Companies, H1 2012 16
Number of Products under Development by Companies, H1 2012 (Contd..1) 17
Number of Products under Development by Companies, H1 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 26
Comparative Analysis by Late Stage Development, H1 2012 27
Comparative Analysis by Mid Clinical Stage Development, H1 2012 28
Comparative Analysis by Early Clinical Stage Development, H1 2012 29
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 30
Products under Development by Companies, H1 2012 31
Products under Development by Companies, H1 2012 (Contd..1) 32
Products under Development by Companies, H1 2012 (Contd..2) 33
Products under Investigation by Universities/Institutes, H1 2012 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 47
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 48
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 49
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 50
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 51
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 52
Bristol-Myers Squibb Company, H1 2012 53
Genzyme Corporation, H1 2012 54
F. Hoffmann-La Roche Ltd., H1 2012 55
Amgen Inc., H1 2012 56
Sanofi-Aventis, H1 2012 57
Eli Lilly and Company, H1 2012 58
GlaxoSmithKline plc, H1 2012 59
Merck & Co., Inc., H1 2012 60
Infinity Pharmaceuticals, Inc., H1 2012 61
ZIOPHARM Oncology, Inc., H1 2012 62
Novartis AG, H1 2012 63
ImClone Systems Incorporated, H1 2012 64
Auxilium Pharmaceuticals, Inc., H1 2012 65
Eisai Co., Ltd., H1 2012 66
Menarini Group, H1 2012 67
Alchemia Limited, H1 2012 68
Celldex Therapeutics, Inc., H1 2012 69
AIDA Pharmaceuticals, Inc., H1 2012 70
Cleveland BioLabs, Inc., H1 2012 71
Oncolytics Biotech Inc., H1 2012 72
ARQULE, INC, H1 2012 73
TopoTarget A/S, H1 2012 74
CytRx Corporation, H1 2012 75
Pharmacyclics, Inc., H1 2012 76
Threshold Pharmaceuticals, Inc., H1 2012 77
PCI Biotech AS, H1 2012 78
MabVax Therapeutics, Inc., H1 2012 79
Nanobiotix, H1 2012 80
Morphotek, Inc., H1 2012 81
Vaccinex, Inc., H1 2012 82
S*BIO Pte Ltd, H1 2012 83
Neotropix, Inc., H1 2012 84
Jennerex Biotherapeutics, Inc., H1 2012 85
Axelar AB, H1 2012 86
MolMed S.p.A., H1 2012 87
BiPar Sciences, Inc., H1 2012 88
PharmaMar, S.A., H1 2012 89
AVEO Pharmaceuticals, Inc., H1 2012 90
Polaris Group, H1 2012 91
Epeius Biotechnologies Corporation, H1 2012 92
Assessment by Monotherapy Products, H1 2012 93
Assessment by Combination Products, H1 2012 94
Assessment by Stage and Route of Administration, H1 2012 97
Assessment by Molecule Type, H1 2012 100
Sarcomas Therapeutics – Drug Profile Updates 170
Sarcomas Therapeutics – Discontinued Products 178
Sarcomas Therapeutics – Discontinued Products (Contd..1) 179
Sarcomas Therapeutics – Dormant Products 180
Sarcomas Therapeutics – Dormant Products (Contd..1) 181
Sarcomas Therapeutics – Dormant Products (Contd..2) 182
Sarcomas Therapeutics – Dormant Products (Contd..3) 183
Sarcomas Therapeutics – Dormant Products (Contd..4) 184
Sarcomas Therapeutics – Dormant Products (Contd..5) 185
Sarcomas Therapeutics – Dormant Products (Contd..6) 186
Sarcomas Therapeutics – Dormant Products (Contd..7) 187
Sarcomas Therapeutics – Dormant Products (Contd..8) 188
Sarcomas Therapeutics – Dormant Products (Contd..9) 189
Sarcomas Therapeutics – Dormant Products (Contd..10) 190
List of Figures
Number of Products under Development for Sarcomas, H1 2012 13
Products under Development for Sarcomas – Comparative Analysis, H1 2012 14
Products under Development by Companies, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 19
Late Stage Products, H1 2012 27
Mid Clinical Stage Products, H1 2012 28
Early Clinical Stage Products, H1 2012 29
Pre-Clinical Stage Products, H1 2012 30
Assessment by Monotherapy Products, H1 2012 93
Assessment by Combination Products, H1 2012 94
Assessment by Route of Administration, H1 2012 95
Assessment by Stage and Route of Administration, H1 2012 96
Assessment by Molecule Type, H1 2012 98
Assessment by Stage and Molecule Type, H1 2012 99
[Tabellenverzeichnis ausblenden]